Luciferase Reporter Cell Line - MV4-11

RUNX1, once a tumor suppressor, is now known for its oncogenic role in AML development. The researchers elucidate the dual role of RUNX1 in acute myeloid leukemia (AML) by investigating its impact on AML cell propagation. Through RUNX1 knockdown experiments of varying degrees, they observed that moderate attenuation of RUNX1 facilitated AML cell proliferation by accelerating the cell cycle, while profound depletion induced cell-cycle arrest and apoptosis. This moderate attenuation also triggered compensatory upregulation of RUNX2 and RUNX3, collectively elevating total RUNX expression. Consequently, increased transactivation of GSTA2 ensued, promoting ROS catabolization and cell-cycle progression, ultimately enhancing AML cell proliferation.

Figure 1. The researchers aimed to investigate the impact of GSTA2-mediated ROS removal on AML cell proliferation. They conducted experiments measuring intracellular ROS levels in MV4-11 cells under various conditions, including RUNX1 knockdown, GSTA2 knockdown, and β-lapachone treatment. Flow cytometric analysis assessed cell cycle progression. Results suggest that reducing intracellular ROS levels via GSTA2 may promote AML cell proliferation. (Morita K, et al., 2017)

Utilizing Creative Biogene's Luciferase Reporter Cell Line - MV4-11 streamlines experimental procedures. With built-in luciferase reporter genes, there's no need for cloning or transfecting promoter regions. Researchers can directly assess promoter activity by transfecting their expression vectors and measuring luciferase activity, saving time and effort while reducing experimental complexity.